Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 142 clinical trials
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL

zanubrutinib for newly-diagnosed Mantle Cell Lymphoma (MCL).

dexamethasone
mantle cell lymphoma
cytarabine
oxaliplatin
TP53
  • 0 views
  • 24 May, 2022
  • 2 locations
A Pilot Study of Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Resistant Mantle Cell Lymphoma (MCL) - the MCL MATCH Trial

This clinical trial collects and tests samples using genetic testing to find personalized treatments that may work best for patients with mantle cell lymphoma (MCL) that has come back (relapsed

  • 0 views
  • 21 Oct, 2022
  • 1 location
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Bcl-2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma

relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.

  • 0 views
  • 23 Oct, 2022
  • 7 locations
Avo In R/R And Previously Untreated MCL

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell

acalabrutinib
neutrophil count
monoclonal antibodies
TP53
obinutuzumab
  • 0 views
  • 04 Oct, 2022
  • 2 locations
Consolidation With ADCT-402 (Loncastuximab Tesirine) After a Short Course of Immunochemotherapy: a Phase II Study in BTKi-treated (or BTKi Intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients (FIL_COLUMN)

immunochemotherapy in BTKi (Bruton Tyrosine Kinase inhibitors) -treated (or BTKi intolerant) R/R (Relapse or Refractory) MCL (Mantle Cell Lymphoma) patients. The sponsor of this clinical trial is Fondazione Italiana

  • 0 views
  • 17 Oct, 2022
  • 3 locations
An Open-label, Phase 1/2, First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of NVG-111 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma

) and mantle cell lymphoma (MCL). NVG-111 is a bispecific antibody drug, having two "arms", one arm attaches to a substance on cancer cells called ROR1, the other arm attaches to the body's immune cells

gilbert's syndrome
monoclonal antibodies
cancer
venetoclax
monoclonal protein
  • 0 views
  • 20 Oct, 2022
  • 1 location
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the

acalabrutinib
b-cell lymphoma
leukemia
marginal zone lymphoma
lymphocytic leukemia
  • 108 views
  • 07 Oct, 2022
  • 29 locations
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

/refractory (R/R) mature B-cell malignancies; in combination with zanubrutinib in participants with R/R follicular lymphoma (FL), R/R mantle cell lymphoma (MCL) or R/R diffuse large B-cell lymphoma (DLBCL

large b-cell lymphoma
diffuse large b-cell lymphoma
urothelial carcinoma
b-cell lymphoma
cancer
  • 24 views
  • 04 Oct, 2022
  • 11 locations
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

), follicular lymphoma (FL) or mantle cell lymphoma (MCL) (stratum II) as well as paediatric patients with r/r ALL (stratum III) will be treated with autologous T-lymphocytes transduced by the third-generation

large b-cell lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
leukemia
hodgkin's disease
  • 40 views
  • 14 Feb, 2022
  • 1 location
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

This is a Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR1) that is found on hematologic tumor cells. ROR1 has …

thrombocytopenia
leukemia
neutrophil count
monoclonal antibodies
renal function tests
  • 56 views
  • 08 Nov, 2020
  • 4 locations